Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs has a long history of providing high-quality services and products to provide customers with reliable support for CAR-T cell therapy research. Please browse the following CCR8 CAR-related products that we can provide.
CCR8 is a chemokine receptor that is specifically highly expressed on tumor-infiltrating regulatory T cells (Tregs) and is also expressed in Th2 cells and tumor cells, but is rarely expressed on peripheral blood Treg or normal tissues. CCR8 is involved in the recruitment of Treg and Th2 cells to inflammation and tumor sites, and its high expression is associated with a variety of cancers, including colorectal cancer, breast cancer, gastric cancer, metastatic brain cancer, metastatic liver cancer, etc., and is considered to be a potential specific marker of Treg at tumor sites and a promising tumor immune target. Studies have shown that the development of monoclonal antibody drugs targeting CCR8 is beneficial for the specific inhibition of the function of Treg at tumor sites, which is helpful for cancer treatment.
Fig.1 Location of CCR8 on tumor Treg cells.1
Colorectal Cancer
Gastric Cancer
Metastatic Brain Cancer
Metastatic Liver Cancer
Anti-CCR8 CAR-T Expression Test
Creative Biolabs provides in vitro expression and function studies of anti-CCR8 CAR T cells. The figure below investigates whether CCR8 CAR T cells inhibit T cell function. The results showed that there were differences in the expression level of CCR8 in different CAR construction methods.
Fig.2 Detection of the expression of CCR8 CAR T cells by flow cytometry.2
Anti-CCR8 CAR-T Cytokine Release Test
Creative Biolabs provides in vitro cytokine release assays for anti-CCR8 CAR T cells. As shown in Figure 2, we provide a multiplex immunoassay to analyze the concentration of indicator cytokines in the CCR8 CAR T cell supernatant.
Fig.3 The levels of granzyme-B and IFN-γ in CCR8 CAR T cell were determined by ELISA.2
Anti-CCR8 CAR-T In Vitro Cytotoxicity Assay
Creative Biolabs offers in vitro cytotoxicity testing services for anti-CCR8 CAR T cells. As shown in Figure 4, cytotoxicity assays were performed on different construct CCR8 CAR T cells in the ATLL cell line, and the results showed that C1028z and C1928z T exhibited higher cytotoxicity.
Fig.4 Cytolytic activity of anti-CCR8 CAR-T in ATLL cell lines.2
Anti-CCR8 CAR-T Cell Therapy Animal Models
The selection of appropriate animal models provides a scientific basis for the preclinical study of CCR8 CAR-T therapy. Creative Biolabs offers a variety of animal models for in vivo CCR8 CAR-T studies, such as immunodeficient NSI mice, which have been used in several articles. At the same time, the in vivo efficacy of CCR8 CAR-T was evaluated by using bioluminescence imaging (BLI) and other methods to detect the required indicators in the model.
Fig.5 Schematic diagram of in vivo model construction of anti-CCR8 CAR-T cells.2
Efficacy Test of Anti-CCR8 CAR-T
Creative Biolabs provides in vivo efficacy evaluation services to customers based on suitable animal models. As shown in Figure 6, CCR8 CAR T cells have excellent results in prolonging survival.
Fig.6 Growth curves of mouse tumors treated with CCR8 CAR T cells.3
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-0622-LX595 | Anti-CCR8 (X6X273) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X273 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX596 | Anti-CCR8 (X6X274) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X274 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX597 | Anti-CCR8 (X6X275) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X275 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX598 | Anti-CCR8 (X6X276) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X276 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX599 | Anti-CCR8 (X6X277) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X277 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX600 | Anti-CCR8 (X6X278) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X278 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX601 | Anti-CCR8 (X6X279) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X279 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX602 | Anti-CCR8 (X6X280) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X280 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX603 | Anti-CCR8 (X6X281) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X281 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX604 | Anti-CCR8 (X6X282) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X282 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX605 | Anti-CCR8 (X6X283) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X283 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX606 | Anti-CCR8 (X6X284) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X284 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX607 | Anti-CCR8 (X6X285) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X285 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX608 | Anti-CCR8 (X6X286) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X286 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX609 | Anti-CCR8 (X6X287) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X287 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX610 | Anti-CCR8 (X6X288) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X288 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX611 | Anti-CCR8 (X6X289) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X289 | Human | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX612 | Anti-CCR8 (X6X290) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X290 | Human | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX613 | Anti-CCR8 (X6X291) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X291 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-LX614 | Anti-CCR8 (X6X292) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X6X292 | mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
